Vol. 5 No. 7 (2025)
Reimbursement Recommendations

Polatuzumab Vedotin (Polivy)

decorative image of the issue cover

Published July 23, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) should be reimbursed by public drug plans for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, Epstein-Barr virus–positive DLBCL not otherwise specified, and T-cell/histiocyte-rich LBCL that is classified as activated B cell–like (ABC) subtype if certain conditions are met.
  • Polivy in combination with R-CHP should only be covered to treat adult patients who have previously untreated ABC subtype of LBCL confirmed with appropriate testing. Eligible patients should have low to intermediate risk of survival on the International Prognostic Index scale and good performance status. Patients with LBCL not classified as ABC subtype of LBCL are not eligible for Polivy in combination with R-CHP.
  • Polivy in combination with R-CHP should only be reimbursed if prescribed by clinicians with experience in the management of aggressive lymphomas and the side effects of treatment with curative intent and the cost of Polivy is reduced.